Replies to post #25312 on BioSante Pharmaceuticals, Inc. (BPAX)

[nutsyprofessor]

"ANI's revenue estimates were at $106 million by 2016 and $143.6 million by 2017,"

JTFM, correct me if I'm wrong but I believe these estimates might have included Biosante's pipeline the mix? Or, if it wasn't specifically stated, how do we really know if it was or wasn't?

[QyQ]

JTFM,

What !!!! ANI's revenue only estimates were at $106 million by 2016 and $143.6 million by 2017.

BPAX already had revenue more than $250 million at 2014 and could reach more than $500 million at 2017 when libigel being marketed to worldwide. This is for off-label Libigel alone, not yet add up revenue for HSDD libigel + Bio-T

Future fair ratio shown BPAX value 10X more than ANI. So the fair % ownership should be 90% BPAX and 10% ANI as for now.

ANI have a business plan, BPAX don't have business plan? BPAX should BUYOUT ANI along the way so that BPAX to the equation with both manufacturing and sales capabilities becomes magnified in the event Abbvie wish to co-promote/develop Libigel.

I only agree if the % ownership is 90% BPAX and 10% ANI.